Singapore Fling: AbbVie says a plant in Asia is just what it needs

Abbvie, which spun off from Abbott Laboratories since early last year, has picked Singapore for the location of a new manufacturing plant to handle ingredients for small-molecule and biologic drugs for oncology and immunology drug candidates. According to Abbvie, this move could help alleviate the problem of decrease in revenue when Humira, its best-selling drug, goes off patent in 2016, and to balance out the supply chain with its numerous plants in North America and Europe. A interferon-freeĀ  hepatitis C product is its most anticipated candidate, as they expect up to 90% of patients to be cured when used with a combo of other drugs.

Read more at:

Leave a Reply

Your email address will not be published. Required fields are marked *